• PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 3 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 3 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…

  • PubMed
  • April 18, 2025
  • 2 views
Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients

BMJ Open Respir Res. 2025 Apr 17;12(1):e002206. doi: 10.1136/bmjresp-2023-002206. ABSTRACT BACKGROUND: Vilobelimab, a first in class C5a-specific monoclonal antibody, improved 28-day and 60-day mortality in intubated COVID-19 patients in PANAMO,…